



# **APHL New Disorders National Meeting: MPS I - Experience in Illinois**

**Claudia Nash, M.S.**

**Newborn Screening Follow-Up Manager**


June 22, 2017

# OVERVIEW

- **ILLINOIS NBS PROGRAM**
- **PREPARATION FOR MPS I**
- **EXPECTING THE UNEXPECTED**
- **OUTCOME: 2 YEARS LATER**

# ILLINOIS NBS PROGRAM

## Office of Health Protection **Laboratory** (Chicago)



- Develop new tests
- Test for disorders  
~150,000 births  
annually

## Office of Health Promotion **Follow-up** (Springfield)



- Report/Follow-up all  
abnormal results
- Compile case data
- Interact with specialists

# PREPARATION

- **FOLLOW-UP PROGRAM**  
(ADDED SCREENING FOR 5 LSDS JUNE 2015)
  - ADMINISTRATIVE CODE CHANGES/FEE INCREASE
  - DETERMINE STAFFING NEEDS
  - OBTAIN CLINICAL INPUT (LSD SUBCOMMITTEE)
  - DETERMINE REPORTING AND F/U PROTOCOLS
  - DEFINE DATA ELEMENTS
  - PROVIDE EDUCATION

# PREPARATION

- **ADMINISTRATIVE CODE CHANGES**
  - DEFINE CRITERIA FOR DESIGNATION OF SPECIALISTS
  - INCREASE NBS FEE
  
- **STAFFING**
  - HIRED TWO FOLLOW-UP STAFF MEMBERS TO SUPPORT ADDITION OF TESTING FOR MULTIPLE LSDS

# PREPARATION

- **OBTAIN CLINICAL INPUT**
  - **DESIGNATE REFERRAL CENTERS**
    - SEVEN HOSPITAL SYSTEMS
    - INCLUDES TWO IN THE ST. LOUIS AREA (MISSOURI)
  - **MULTIDISCIPLINARY LYSOSOMAL STORAGE SUBCOMMITTEE**
    - STAFF FROM ALL CENTERS INCLUDED
    - MET MONTHLY/CONTINUE TO MEET
    - PROVIDED INPUT ON WHAT DIAGNOSTIC AND LONG TERM FOLLOW-UP DATA TO COLLECT
    - ESTABLISHED STANDARDIZED CLINICAL DIAGNOSTIC PROTOCOLS

# PREPARATION

- **REPORTING/FOLLOW-UP PROTOCOLS**
  - **UTILIZE SAME PROTOCOL USED FOR OTHER NBS DISORDERS**
    - **REPORT RESULTS TO PCP BY PHONE/FAX/MAIL**
    - **FOLLOW-UP WITH PCP IN 1-2 DAYS TO ASSURE REFERRAL**
    - **ONCE REFERRED, FOLLOW WITH SPECIALIST TO OBTAIN DX RESULTS (2 WEEK INTERVALS)**

# PREPARATION

- DATA ELEMENTS
  - MAKE CHANGES TO PERKIN ELMER DATABASE
  - DEVELOP CONSENT FORM (ALLOW SPECIALISTS TO DISCUSS CASES/SHARE BLOOD SPOT)
  - DETERMINE DIAGNOSTIC INFORMATION TO COLLECT
    - ENZYME LEVELS
    - URINE GAGS
    - MOLECULAR RESULTS
  - DETERMINE ANNUAL LTFU DATA ELEMENTS TO COLLECT

# PREPARATION

- **EDUCATION**

- DEVELOP PHYSICIAN FACT SHEET
- NOTIFY BIRTH HOSPITALS
- COLLABORATE WITH AAP (STATE CHAPTER) AND IAFP
- ISSUE PRESS RELEASES

# EXPECTING THE UNEXPECTED

- **INSURANCE ISSUES**
  - TIME INVOLVED IN MOLECULAR TESTING APPROVAL
  - COVERAGE DENIED IN SOME CASES
- **CASE CATEGORIZATION CONUNDRUM!**
  - PSEUDODEFICIENCIES/VARIANTS OF UNKNOWN SIGNIFICANCE
  - DETERMINE RESPONSIBILITY OF STATE NBS PROGRAM RE: TRACKING VUS CASES-LONG TERM

# EXPECTING THE UNEXPECTED

## MPS I CASE DETERMINATION

ASSESSMENT	Severe	Attenuated	Pseudo	Undeter- mined	Carriers
Enzyme	Deficient	Deficient	Deficient	Deficient	Deficient
Urine GAGS	Elevated	Elevated	Normal	Normal	Normal
	And 2 pathogenic variants predicting severe phenotype	And 1 or 2 pathogenic variants predictive of attenuated disease	And 1 or more Pseudodeficiency alleles (A79T, H82Q, D223N, and V322E)	And 1 pathogenic variant and one VUS (in trans)	And 1 pathogenic variant
Genetics	Or 1 or 2 VUS with clinical findings consistent with severe phenotype			Or 2 VUS (in trans)	
	Or 1 pathogenic variant with clinical findings consistent with severe disease				

# **OUTCOME: 2 YEARS LATER**

- **SCREENED ~320,000 BIRTHS**
- **ONE MPS I CASE DIAGNOSED**
- **NBS PROGRAM WILL TRACK VUS CASES ANNUALLY**

# OUTCOME: 2 YEARS LATER

- **MPS I**
  - **BORDERLINE SCREENING RESULTS (44%)**
    - IDUA >14% AND  $\leq$ 18%
    - 88% CLOSED AS NORMAL WITH SUBSEQUENT NBS
    - 10% CLASSIFIED AS CARRIER OR PSEUDODEFICIENCY
    - 2% VUS
  - **POSITIVE SCREENING RESULTS (56%)**
    - IDUA  $\leq$  14%
    - 56% CLOSED AS NORMAL (20% THROUGH DX ENZYME TESTING ALONE)
    - 38% CLASSIFIED AS CARRIER OR PSEUDODEFICIENCY
    - 6% VUS
    - <<1% MPS I

# OUTCOME: 2 YEARS LATER

- **MANY PSEUDODEFICIENCIES**
  - **ABNORMAL SCREENING RESULTS WERE COMMONLY DUE TO PSEUDODEFICIENCIES**
  - **OF ALL IDUA VARIANTS, A79T – MOST COMMONLY IDENTIFIED (AA VARIANT)**



**THANK YOU**

**[CLAUDIA.NASH@ILLINOIS.GOV](mailto:CLAUDIA.NASH@ILLINOIS.GOV)**